Suwanee, GA, April 23, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- SANUWAVE Health, Inc. (OTCQB: SNWV) ( www.sanuwave.com) announced they have entered North and South Carolina as their 5th and 6th markets in 2019, also hiring David Cummings to lead SANUWAVE in the Carolinas. SANUWAVE is excited to execute on their commercialization plan to enter into 6 states in 2019 by adding the Carolinas. David joins SANUWAVE from Integra and previously Derma Science, which was acquired by Integra in 2017. Mr. Cummings will participate and help SANUWAVE launch the dermaPACE System in the Carolinas this weekend.
SANUWAVE Health, Inc. is an emerging regenerative medicine company focused on the development and commercialization of noninvasive, biological response activating devices for the repair and regeneration of tissue, musculoskeletal and vascular structures.
SANUWAVE is proud to be a sponsor for the Modern Wound Care Management (MWCM) meeting taking place April 26-27, 2019 in Greensboro, NC. The MWCM mission is to provide the highest quality continuing education experience to all clinicians who care for patients with chronic wounds. This event is a true interdisciplinary approach to wound care with input from multiple specialties. It is designed for more proactive audience participation and interaction with national experts in wound care, including physicians, podiatrists, nurses, physical therapists and other wound care modality providers.
David has been a Carolina resident for decades. President, Shri Parikh, comments, “David’s work in wound care, and the diabetic population, helped him significantly contribute to Derma Science’s rapid growth prior to being acquired by Integra. David’s work in DFU treatment as an expert in Total Contact Casting gives him a great deal of credibility among wound care professionals. David supported this clinical and market growth as an individual contributor, trainer and leader during his eleven-year tenure. We are excited to have him join our team and confident he’ll deliver equally impressive results.”
“We began 2019 with the objective of placing 100 devices. To achieve this, we are focusing on 6 states which cover 33% of the US population. These states were chosen based on three criteria: population density of diabetics, favorable insurance environments for new products and devices, and the ability of SANUWAVE to support and educate the commercialization roll out plan. By entering the Carolinas we have now entered all six states for 2019 and will now begin to place devices rapidly and educating and certifying our clinical users. As usage increases in these states we should begin to experience a positive reimbursement environment due to the strong benefits the device brings to treating DFU’s,” said Kevin Richardson, CEO.
About SANUWAVE Health, Inc.
SANUWAVE Health, Inc. (OTCQB:SNWV) (www.sanuwave.com) is a shock wave technology company initially focused on the development and commercialization of patented noninvasive, biological response activating devices for the repair and regeneration of skin, musculoskeletal tissue and vascular structures. SANUWAVE’s portfolio of regenerative medicine products and product candidates activate biologic signaling and angiogenic responses, producing new vascularization and microcirculatory improvement, which helps restore the body’s normal healing processes and regeneration. SANUWAVE applies its patented PACE® technology in wound healing, orthopedic/spine, plastic/cosmetic and cardiac conditions. Its lead product candidate for the global wound care market, dermaPACE®, is US FDA cleared for the treatment of Diabetic Foot Ulcers. The device is also CE Marked throughout Europe and has device license approval for the treatment of the skin and subcutaneous soft tissue in Canada, South Korea, Australia and New Zealand. SANUWAVE researches, designs, manufactures, markets and services its products worldwide, and believes it has demonstrated that its technology is safe and effective in stimulating healing in chronic conditions of the foot (plantar fasciitis) and the elbow (lateral epicondylitis) through its U.S. Class III PMA approved OssaTron® device, as well as stimulating bone and chronic tendonitis regeneration in the musculoskeletal environment through the utilization of its OssaTron, Evotron® and orthoPACE® devices in Europe, Asia and Asia/Pacific. In addition, there are license/partnership opportunities for SANUWAVE’s shock wave technology for non-medical uses, including energy, water, food and industrial markets.
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future business development activities and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with the regulatory approval and marketing of the Company’s product candidates and products, unproven pre-clinical and clinical development activities, regulatory oversight, the Company’s ability to manage its capital resource issues, competition, and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.
For additional information about the Company, visit www.sanuwave.com.
Millennium Park Capital, LLC
SANUWAVE Health, Inc.
Kevin Richardson II
Chairman of the Board